Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 – September 2, 2016, in Munich, Germany

by | Jul 31, 2016 | Event

Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 – September 2, 2016, in Munich, Germany

Dr. Christoph Wiessner, COO will participate in a panel discussion on the update and future directions on clinical trials in Frontotemporal Dementia and associated disorders.

Posted :

Have a look at the FTD Conference report

Asceneuron to present at the 1st European Conference on Drug Discovery for Neurodegeneration on 15-17 May, 2016 in Budapest, Hungary

by | May 17, 2016 | Event

Asceneuron to present at the 1st European Conference on Drug Discovery for Neurodegeneration on 15-17 May, 2016 in Budapest, Hungary

Dr. Dirk Beher, CEO will present on Founding and Funding of a Biotechnology Company. The Alzheimer’s Drug Discovery Foundation is hosting its first European conference on Drug Discovery for Neurodegeneration: An Educational Course on Translating Research into Drugs which is based on the ADDF’s annual US-based Drug Discovery for Neurodegeneration conference.

Posted :

More about this event

Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.

by | Nov 10, 2015 | Press releases

Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.

Asceneuron SA, an emerging leader in the development of innovative small molecules targeting tauopathies such as progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurodegenerative diseases, today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.

“We are extremely pleased to welcome Hans Schikan as Chairman to our Board of Directors in recognition of the rapid progress the company has made in the development of drug candidates for rare tauopathies which is supported by our recent CHF 30 million Series A financing round” said Dirk Beher (PhD), Chief Executive Officer and a Founder of Asceneuron. “Hans’ vast orphan drug development expertise will help us tremendously in moving this company toward our ultimate goal to bring new medicines to patients and their families.”

Hans Schikan is former Chief Executive Officer of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he worked at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently Chairman of the Board of Complix (Belgium) and InteRNA Technologies (Netherlands). In addition, he is Board Member of Hansa Medical, Sobi and Wilson Therapeutics (Sweden). He is also Member of the Top Team of the Dutch Top Sector Life Sciences & Health and Adviser of Khondrion (Netherlands).

“I am delighted to join Asceneuron at this exciting time in the company’s development, with solid science, a promising pipeline, a great team and a strong syndicate of investors” said Hans Schikan. “I look forward to adding my experience and helping the team to develop its products in progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurodegenerative diseases, which represent a huge medical need.”

Posted :

About Asceneuron

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The company’s pipeline reflects its ambition and commitment to developing treatments for a wide a range of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease, as well as orphan tauopathies. Asceneuron has two clinical-stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies: OGA inhibitor ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class OGA inhibitor, ASN51 for Alzheimer’s disease. Asceneuron is backed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.